A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
11/2002
11/06/2002	EP1157024B1 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
11/06/2002	EP0825861B1 High-dose chromic tripicolinate for the treatment of type ii diabetes
11/06/2002	CN1378591A Bacterial protection
11/06/2002	CN1378551A 嘌呤衍生物 Purine derivatives
11/06/2002	CN1378550A Partial or full A1 agonists-N6 heterocyclic 5' thio substituted adenosine devivatives
11/06/2002	CN1378544A Substituted azoles compounds
11/06/2002	CN1378541A Inhibitors of c-JUN N-terminal kinase (JNK) and other protein kinases
11/06/2002	CN1378537A 嘧啶衍生物 Pyrimidine derivatives
11/06/2002	CN1378527A Biaryl ether derivatives useful as monoamine reuptake inhibitors
11/06/2002	CN1378459A Treatment of auto immune diseases with antagonists which bind to B cell surface markers
11/06/2002	CN1378454A Aminoalkylenephosphonates for treatment of bone disorders
11/06/2002	CN1378449A Iron chelators and use thereof
11/06/2002	CN1378441A Use of conjugated linoleic acid (CLA) for topical treatment of cellulite
11/06/2002	CN1377897A Viva pertusa polyose for regulating blood fat and its preparing method
11/06/2002	CN1377887A Polypeptide for inhibiting growth and migration of blood vessel endothelial cell and endothelial stem cell and its preparing method and use
11/06/2002	CN1377880A Compound for curing vascular complication, its preparing method and treating use
11/06/2002	CN1377879A New alpha-amino acid sulfuryl compounds, its preparing method and medicinal composition containing them
11/06/2002	CN1377673A Natural medicine for treating hyperlipemia and hyperglycemia diseases
11/06/2002	CN1377670A Long life tea for curing various diseases
11/06/2002	CN1377664A Pill for clearing away liver fire and reducing fat
11/06/2002	CN1377652A Method for preparing micro element concentrated mineral liquid
11/06/2002	CN1377642A Use of compound for preparing medicine for curing and preventing non-insulin dependent diabetes or obesity
11/06/2002	CN1093767C Protein kinase C inhibitors
11/06/2002	CN1093759C 蛋白激酶c抑制剂 Protein kinase c inhibitor
11/05/2002	US6476193 NLK1 protein and NLK1 protein complexes
11/05/2002	US6476187 Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
11/05/2002	US6476060 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
11/05/2002	US6476059 Use of polycyclic 2-aminothiazole systems for the treatment of obesity
11/05/2002	US6476044 Use of morphine derivatives as medicaments for the treatment of neuropathic problems
11/05/2002	US6476038 Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
11/05/2002	US6476026 Compounds and compositions as protease inhibitors
11/05/2002	US6476023 Aromatic heterocyclic compounds as anti-inflammatory agents
11/05/2002	US6476010 Orally administering to a post-menopausal woman a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of l-carnitine or salts
11/05/2002	US6476006 Compact form for oral administering; bone disorders
11/05/2002	US6475534 Ginkgo biloba composition, method to prepare the same and uses thereof
11/05/2002	US6475532 Calcium channel antagonist possessing an inhibitory action against secretion of parathyroid hormones and a use thereof
11/05/2002	US6475521 Biphasic controlled release delivery system for high solubility pharmaceuticals and method
11/05/2002	US6475493 Controlled release pellet formulation
11/05/2002	US6475480 Use of adenoviral E4 reading frames to improve expression of a gene of interest
11/05/2002	CA2138925C Method of producing reconstituted lipoproteins
11/05/2002	CA2110166C Tableting of colestipol hydrochloride
11/05/2002	CA2109322C Bombesin analogs
11/05/2002	CA2037779C Antibiotic ge 2270 factors b1, b2, c1, c2, d1, d2, e and t
11/01/2002	CA2384227A1 Combination treatment for anxiety and depression
10/2002
10/31/2002	WO2002086156A2 New polynucleotides and polypeptides of the ifn$g(a)-17 gene
10/31/2002	WO2002086107A2 A method for differentiating stem cells into insulin-producing cells
10/31/2002	WO2002086087A2 Cytokine protein family
10/31/2002	WO2002086078A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
10/31/2002	WO2002086069A2 Secreted proteins
10/31/2002	WO2002085945A2 Vhh single heavy chain antibody and a method for its preparation in a mammal
10/31/2002	WO2002085944A2 Single chain camelid vhh antibodies, method for their production in a mammal and their uses
10/31/2002	WO2002085940A2 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002	WO2002085938A1 Anti-obesity polypeptides
10/31/2002	WO2002085930A2 Immunomodulating agents from parasitic worms and method for isolation thereof
10/31/2002	WO2002085925A2 Melanocortin receptor ligands
10/31/2002	WO2002085899A1 Heterocyclyldicarbamides as caspase inhibitors
10/31/2002	WO2002085897A1 Heterocyclic compounds for aging-related and diabetic vascular complications
10/31/2002	WO2002085892A1 Heterocyclyloxy-, -thioxy- and -aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands
10/31/2002	WO2002085891A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
10/31/2002	WO2002085888A1 Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
10/31/2002	WO2002085886A2 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002	WO2002085868A1 Benzoxazinone derivatives for use in the treatment of angiogenesis
10/31/2002	WO2002085859A1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
10/31/2002	WO2002085851A1 Pyrrole derivative
10/31/2002	WO2002085844A1 New compounds
10/31/2002	WO2002085843A2 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
10/31/2002	WO2002085383A1 Method for reducing copper levels and treating copper toxicosis
10/31/2002	WO2002085382A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002	WO2002085381A1 Method for treating gout and binding uric acid
10/31/2002	WO2002085380A1 Method for treating gout and reducing serum uric acid
10/31/2002	WO2002085378A1 Low salt forms of polyallylamine
10/31/2002	WO2002085377A1 Method for lowering serum glucose
10/31/2002	WO2002085376A2 A method for decreasing superoxide anion production and for the treatment of diseases associated with oxidative stress
10/31/2002	WO2002085368A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002	WO2002085361A1 Benzimidazolone compounds
10/31/2002	WO2002085357A1 Nociceptin analogs
10/31/2002	WO2002085354A1 Spiroindene and spiroindane compounds
10/31/2002	WO2002085330A1 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/31/2002	WO2002085306A2 Use of follistatin to increase muscle mass
10/31/2002	WO2002085293A2 Production of alpha-lipoic acid
10/31/2002	WO2002068585A3 Tip39 polypeptides
10/31/2002	WO2002068381A3 Aryl-n-cyanoguanidines and methods related thereto
10/31/2002	WO2002055547A9 Sfrp and peptide motifs that interact with sfrp and methods of their use
10/31/2002	WO2002051428A8 Sympathetic-activating perfume composition
10/31/2002	WO2002049650A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives
10/31/2002	WO2002042455A3 Modifier of organelle metalbolism
10/31/2002	WO2002030415A9 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
10/31/2002	WO2002022611A3 Caspase inhibitors and uses thereof
10/31/2002	WO2002013806A3 Compositions containing hypotriglyceridemically active stilbenoids
10/31/2002	WO2001067896A3 Method of producing oily suspensions of water-soluble vitamins
10/31/2002	WO2001044243A3 Novel heteroaryl-diazabicycloalkanes
10/31/2002	WO2000062766A3 Uses of ppar-gamma agonists in neutrophil-induced diseases
10/31/2002	US20020161169 Hydrogel-forming system with hydrophobic and hydrophilic components
10/31/2002	US20020161042 Nitric oxide donor composition and method for treatment of anal disorders
10/31/2002	US20020161039 Crystalline choline ascorbate
10/31/2002	US20020161038 Inosine 5'-monophosphate dehydrogenase (IMPDH); prodrug having functional group -CO-N(-R)-COO-, a carrier, and an immunosuppressant, anticancer agent, antiviral agent, or anti-vascular hyperproliferation agent
10/31/2002	US20020161032 Dosage form of a statin and microparticles of fenofibrate stabilized by a phospholipid surface active substrance; bioavailability unaffected by food intake
10/31/2002	US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002	US20020161019 For treatment of depression, anxiety, feeding disorders, headache, drug addiction, inflammatory disorders
10/31/2002	US20020161014 Purinyl substituted quinazoline-4-one derivatives

1 ... 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 ... 1298